Navigation Links
Delcath Announces Agreement With University Medical Center Schleswig-Holstein for Use of Its Hepatic CHEMOSAT Delivery System
Date:2/16/2012

to, uncertainties relating to: the future use and adoption of the CHEMOSAT system by the University Medical Center Schleswig-Holstein, future initial launch and training agreements with other cancer centers in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
2. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
3. Delcaths Ireland Operations Achieves ISO 13485 Certification
4. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
5. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
6. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
7. Delcath to Present at the Lazard Healthcare Conference on November 15
8. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
9. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
10. FDA Schedules Delcath Pre-New Drug Application Meeting Date
11. Delcath Announces Completion of Regulatory Notification Process in New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, ... an update on its pipeline and new product ... expects to initiate a Phase 2a study of ... developed for the management of patients with acute ... Staccato -based product candidates for development - ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:8/1/2014)... 2014 A new study published ... may contribute to the development of colorectal cancer in ... The study was authored by Alberto Martin of the ... cause intestinal cells to multiply and create tumors in ... , “What’s interesting about this study,” said Shahab ...
(Date:8/1/2014)... Canadian, OK (PRWEB) August 01, 2014 ... graduate from the program at the drug rehab center ... in the year 2001, Narconon Arrowhead is the flagship ... come from across the United States for services there. ... the center has recent outcome studies as well as ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... recently announced the addition of a comprehensive report ... titled ‘Infusion System Market (Large Volume, Disposable, Syringe, ... Share, Growth, Trends And Forecast, 2013 – 2019’ ... website http://www.transparencymarketresearch.com . , To begin with, ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July ... healthier than school cafeteria fare, a new study suggests. ... lunches third and fourth graders brought from home met three ... "Our findings are similar to results of other studies of ... that high-calorie packaged foods and beverages are more common than ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although older women ... make asthma care a priority, according to a new study. ... from asthma much more than men over 65," concluded Dr. ... of Allergy, Asthma and Immunology (ACAAI), in an organization news ... age 65 years and older is nearly four times higher ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2
... April 22 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... investor-focused corporate synopsis on its English,language website, ... as a,pdf document. The synopsis details Aida ... line, the drugs in its,development pipeline, as ...
... leads to adverse reactions identified, officials add , , MONDAY, ... now been found in at least 10 countries, not ... to ensure the safety of the blood thinner, U.S. ... contaminated lots of the blood thinner have been traced ...
... Available in Smaller Package for Healthy Snacking, MINDEN, ... the maker of the award-winning Detour(R) bar, today announced,the ... their top,selling Detour Caramel Peanut Bar(TM). The snack size ... choice for energy seekers living a,healthy lifestyle. With seven ...
... The American College of Allergy,Asthma & Immunology ... surveys that highlight the importance of improving care ... and other important,information for physicians and patients are ... like Sepracor who are,committed to driving the dialogue ...
... SAN JUAN, Puerto Rico, April 22 Triple-S,Management Corporation ... plans,to release financial results for the first quarter ended ... 2008. Ramon M. Ruiz-Comas, President and,Chief Executive Officer, and ... host a conference call to discuss these,results and the ...
... Formation Capital, LLC is,pleased to announce that ... joined the company as Senior Executive Vice President ... be leading the day-to-day,operations and direction of the ... leading change, building shareholder value, and managing Board,and ...
Cached Medicine News:Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:FDA: Contaminated Heparin Found in 11 Countries 2Health News:FDA: Contaminated Heparin Found in 11 Countries 3Health News:FDA: Contaminated Heparin Found in 11 Countries 4Health News:Detour(R) Unveils Snack Size Protein Bar 2Health News:Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast 2Health News:Damian Dell'Anno Joins Formation Capital as Chief Operating Officer 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
S.O.C. Medium...
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: